Zimmer Biomet CFO Suketu Upadhyay Exits Suddenly, Controller Steps In
Medical device giant Zimmer Biomet Holdings (NYSE: ZBH) announced the sudden departure of Chief Financial Officer Suketu Upadhyay, effective April 28, 2026, just six days after he notified the company of his intention to leave for another professional opportunity.
The Change
Suketu Upadhyay is resigning from his role as Chief Financial Officer and Executive Vice President of Finance, Operations and Supply Chain at Zimmer Biomet to pursue a new professional opportunity, according to an 8-K filing with the Securities and Exchange Commission. The company emphasized that his departure is not related to any disagreement concerning financial statements, internal controls, operations, policies, or practices.
Paul Stellato, the company's current Vice President, Controller and Chief Accounting Officer, will assume the interim CFO position while continuing his existing responsibilities. Stellato, 51, will serve as both principal financial officer and principal accounting officer until a permanent successor is named. Zimmer Biomet confirmed that a search for a permanent CFO is already underway.
Background
Stellato brings substantial financial leadership experience to the interim role, having served as Zimmer Biomet's Vice President, Controller and Chief Accounting Officer since May 2022. In his current position, he oversees global controllership and accounting functions while leading the financial planning and analysis team.
Before joining Zimmer Biomet, Stellato spent over a decade at water technology company Xylem Inc., where he held progressively senior finance roles. He joined Xylem at its 2011 spinoff from ITT Corporation and served in various capacities including Vice President Finance for Financial Planning and Analysis (2011-2017), Vice President, Controller and Chief Accounting Officer (2017-2019), and Vice President Finance for Global Business Services (2019-2022).
Stellato's career began in public accounting with Ernst & Young LLP and Arthur Andersen LLP, and he maintains his certification as a public accountant. His experience also includes roles at ITT Corporation from 2003 to 2011, where he served as General Auditor and Manager of Investor Relations.
What It Means
The sudden departure of a CFO with just six days' notice raises questions about succession planning at the Warsaw, Indiana-based medical device manufacturer. While the company has moved quickly to ensure continuity by appointing an experienced internal candidate, the abrupt timeline suggests limited transition planning.
Zimmer Biomet is compensating Stellato for his expanded responsibilities with a significant pay package. His annual base salary increases to $550,000 (prorated for 2026), with a target annual bonus opportunity of 70% of base salary under the company's Executive Performance Incentive Plan. Additionally, he will receive equity awards totaling approximately $850,000, comprising $750,000 in time-vested restricted stock units over three years and $100,000 in performance-based restricted stock units.
The compensation structure signals the company's commitment to maintaining financial leadership stability during the transition period. The three-year vesting schedule for the majority of Stellato's equity awards suggests either confidence in finding a permanent CFO who would retain Stellato in a senior role, or preparation for a potentially extended interim period.
For investors, the key concern will be the pace and quality of the permanent CFO search. Zimmer Biomet, a major player in the orthopedic implant and medical device market, operates in a highly regulated industry where financial expertise in managing complex global operations is critical. The company's ability to attract top-tier financial talent will be closely watched, particularly given the competitive landscape for experienced healthcare CFOs.
The filing reveals no details about Upadhyay's next opportunity or the specific factors that prompted his departure. His exit adds to the normal course of executive transitions in the medical device sector, though the timing and speed of the departure are noteworthy. The company's quick action to name an interim replacement and initiate a formal search process demonstrates preparedness to maintain operational continuity.
Stellato's appointment leverages his deep understanding of Zimmer Biomet's financial operations gained over nearly four years with the company. His prior experience at Xylem, particularly in financial planning and analysis roles, should serve him well in managing investor communications and strategic financial decisions during this transition period. The company has not provided a timeline for completing its CFO search, leaving the duration of Stellato's interim tenure uncertain.